Atrial fibrillation reduction by renal sympathetic denervation: 12 months' results of the AFFORD study.
Ontology highlight
ABSTRACT: AIM:The purpose of this pilot study was to assess whether renal sympathetic denervation (RDN) decreases atrial fibrillation (AF) burden in hypertensive patients with symptomatic AF at 6- and 12-month follow-up, as measured using an implantable cardiac monitor (ICM). METHODS AND RESULTS:A total of 20 patients with symptomatic paroxysmal or persistent AF (EHRA???II) and primary hypertension with a mean office systolic blood pressure (BP) of >?140 mmHg were enrolled. After enrolment, an ICM was implanted 3 months pre-RDN to monitor AF burden. Quality of life (QOL) was assessed using the Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire. Mean age was 64?±?7 years and 55% were females. AF burden in min/day decreased from a median (IQR) of 1.39 (0-11) pre-RDN to 0.67 (0-31.6) at 6 months (p?=?0.64) and to 0.94 (0-6.0) at 12 months (pre-RDN vs. 12 months; p?=?0.03). QOL improved significantly at both 6 months (+?11?±?15 points, p?=?0.006) and 12 months (+?10?±?19, p?=?0.04) as compared to pre-RDN. Office BP decreased significantly at 12-month follow-up (-?20?±?19/-?7?±?10 mmHg), p??0.05) at 12-month follow-up as compared to pre-RDN. CONCLUSION:This pilot study suggests that RDN might be able to decrease AF burden in min/day as measured using an ICM, with a positive effect on QOL. Large-scale randomized trials are needed to prove the definite value of RDN in hypertensive patients with atrial fibrillation.
SUBMITTER: Feyz L
PROVIDER: S-EPMC6529371 | biostudies-literature | 2019 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA